These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

244 related articles for article (PubMed ID: 34625828)

  • 1. Combination of terbium-161 with somatostatin receptor antagonists-a potential paradigm shift for the treatment of neuroendocrine neoplasms.
    Borgna F; Haller S; Rodriguez JMM; Ginj M; Grundler PV; Zeevaart JR; Köster U; Schibli R; van der Meulen NP; Müller C
    Eur J Nucl Med Mol Imaging; 2022 Mar; 49(4):1113-1126. PubMed ID: 34625828
    [TBL] [Abstract][Full Text] [Related]  

  • 2. First-in-Humans Study of the SSTR Antagonist
    Baum RP; Zhang J; Schuchardt C; Müller D; Mäcke H
    J Nucl Med; 2021 Nov; 62(11):1571-1581. PubMed ID: 33674401
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of the tolerability of
    Busslinger SD; Mapanao AK; Kegler K; Bernhardt P; Flühmann F; Fricke J; Zeevaart JR; Köster U; van der Meulen NP; Schibli R; Müller C
    Eur J Nucl Med Mol Imaging; 2024 Jul; ():. PubMed ID: 39046521
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Simultaneous Visualization of
    Borgna F; Barritt P; Grundler PV; Talip Z; Cohrs S; Zeevaart JR; Köster U; Schibli R; van der Meulen NP; Müller C
    Pharmaceutics; 2021 Apr; 13(4):. PubMed ID: 33921467
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Multimodal Imaging of 2-Cycle PRRT with
    Albrecht J; Exner S; Grötzinger C; Prasad S; Konietschke F; Beindorff N; Kühl AA; Prasad V; Brenner W; Koziolek EJ
    J Nucl Med; 2021 Mar; 62(3):393-398. PubMed ID: 32859703
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of the Therapeutic Response to Treatment with a 177Lu-Labeled Somatostatin Receptor Agonist and Antagonist in Preclinical Models.
    Dalm SU; Nonnekens J; Doeswijk GN; de Blois E; van Gent DC; Konijnenberg MW; de Jong M
    J Nucl Med; 2016 Feb; 57(2):260-5. PubMed ID: 26514177
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Somatostatin Receptor Antagonists for Imaging and Therapy.
    Fani M; Nicolas GP; Wild D
    J Nucl Med; 2017 Sep; 58(Suppl 2):61S-66S. PubMed ID: 28864614
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Successful Intra-arterial Peptide Receptor Radionuclide Therapy of DOTATOC-Negative High-Grade Liver Metastases of a Pancreatic Neuroendocrine Neoplasm Using 177Lu-DOTA-LM3: A Somatostatin Receptor Antagonist.
    Zhang J; Kulkarni HR; Singh A; Baum RP
    Clin Nucl Med; 2020 Mar; 45(3):e165-e168. PubMed ID: 31977464
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ga-66 labeled somatostatin analogue DOTA-DPhe1-Tyr3-octreotide as a potential agent for positron emission tomography imaging and receptor mediated internal radiotherapy of somatostatin receptor positive tumors.
    Ugur O; Kothari PJ; Finn RD; Zanzonico P; Ruan S; Guenther I; Maecke HR; Larson SM
    Nucl Med Biol; 2002 Feb; 29(2):147-57. PubMed ID: 11823119
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Radiolabeled Somatostatin Receptor Antagonist Versus Agonist for Peptide Receptor Radionuclide Therapy in Patients with Therapy-Resistant Meningioma: PROMENADE Phase 0 Study.
    Eigler C; McDougall L; Bauman A; Bernhardt P; Hentschel M; Blackham KA; Nicolas G; Fani M; Wild D; Cordier D
    J Nucl Med; 2024 Apr; 65(4):573-579. PubMed ID: 38423782
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A comparison of high- versus low-linear energy transfer somatostatin receptor targeted radionuclide therapy in vitro.
    Nayak T; Norenberg J; Anderson T; Atcher R
    Cancer Biother Radiopharm; 2005 Feb; 20(1):52-7. PubMed ID: 15778581
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Enhancement of somatostatin-receptor-targeted (177)Lu-[DOTA(0)-Tyr(3)]-octreotide therapy by gemcitabine pretreatment-mediated receptor uptake, up-regulation and cell cycle modulation.
    Nayak TK; Atcher RW; Prossnitz ER; Norenberg JP
    Nucl Med Biol; 2008 Aug; 35(6):673-8. PubMed ID: 18678352
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Terbium-161 for PSMA-targeted radionuclide therapy of prostate cancer.
    Müller C; Umbricht CA; Gracheva N; Tschan VJ; Pellegrini G; Bernhardt P; Zeevaart JR; Köster U; Schibli R; van der Meulen NP
    Eur J Nucl Med Mol Imaging; 2019 Aug; 46(9):1919-1930. PubMed ID: 31134301
    [TBL] [Abstract][Full Text] [Related]  

  • 14. DNA double strand breaks as predictor of efficacy of the alpha-particle emitter Ac-225 and the electron emitter Lu-177 for somatostatin receptor targeted radiotherapy.
    Graf F; Fahrer J; Maus S; Morgenstern A; Bruchertseifer F; Venkatachalam S; Fottner C; Weber MM; Huelsenbeck J; Schreckenberger M; Kaina B; Miederer M
    PLoS One; 2014; 9(2):e88239. PubMed ID: 24516620
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Anti-L1CAM radioimmunotherapy is more effective with the radiolanthanide terbium-161 compared to lutetium-177 in an ovarian cancer model.
    Grünberg J; Lindenblatt D; Dorrer H; Cohrs S; Zhernosekov K; Köster U; Türler A; Fischer E; Schibli R
    Eur J Nucl Med Mol Imaging; 2014 Oct; 41(10):1907-15. PubMed ID: 24859811
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Somatostatin-receptor-targeted alpha-emitting 213Bi is therapeutically more effective than beta(-)-emitting 177Lu in human pancreatic adenocarcinoma cells.
    Nayak TK; Norenberg JP; Anderson TL; Prossnitz ER; Stabin MG; Atcher RW
    Nucl Med Biol; 2007 Feb; 34(2):185-93. PubMed ID: 17307126
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Peptide Receptor Radionuclide Therapy in Grade 3 Neuroendocrine Neoplasms: Safety and Survival Analysis in 69 Patients.
    Zhang J; Kulkarni HR; Singh A; Niepsch K; Müller D; Baum RP
    J Nucl Med; 2019 Mar; 60(3):377-385. PubMed ID: 30115686
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Peptide Receptor Radionuclide Therapy with
    Cullinane C; Jeffery CM; Roselt PD; van Dam EM; Jackson S; Kuan K; Jackson P; Binns D; van Zuylekom J; Harris MJ; Hicks RJ; Donnelly PS
    J Nucl Med; 2020 Dec; 61(12):1800-1805. PubMed ID: 32414949
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Design, preparation and biological evaluation of a
    Behnammanesh H; Jokar S; Erfani M; Geramifar P; Sabzevari O; Amini M; Mazidi SM; Hajiramezanali M; Beiki D
    Bioorg Chem; 2020 Jan; 94():103381. PubMed ID: 31662215
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of [(177)Lu-DOTA(0),Tyr(3)]octreotate and [(177)Lu-DOTA(0),Tyr(3)]octreotide: which peptide is preferable for PRRT?
    Esser JP; Krenning EP; Teunissen JJ; Kooij PP; van Gameren AL; Bakker WH; Kwekkeboom DJ
    Eur J Nucl Med Mol Imaging; 2006 Nov; 33(11):1346-51. PubMed ID: 16847654
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.